Press Release

MOLOGEN and MEBO: Joining Forces to Treat Cancer

Berlin, Germany, 2004-04-27

MOLOGEN AG and MEBO International Group, a Chinese pharmaceutical corporation, signed a cooperation agreement. The agreement was signed by Professor Xu, president of MEBO and by MOLOGEN CEO Professor Wittig during a further business trip to Beijing and Guanzhou.
By combining their respective technologies MEBO and MOLOGEN will jointly develop innovative combination treatment against cancer (CoCaT). The efficacy of combined cancer treatment will be evaluated through a clinical try in China. Mologen will contribute their 4-fold gene-modified and immunomodulated tumor cells. MEBO will provide pharmaceutically processed plant (herbal extracts), which induced the differentiation of tumor cells and inhibit metastases formation.
CoCaT, for the very first time, combines "western" DNA and cell technology with "far-eastern" therapeutic approaches, having their origins in traditional Chinese medicines. Scientists and Business Developers of both companies hope that CoCaT will add to the therapeutic success in clinical trials, in comparison to either therapy supplied separately.
MEBO and Mologen will jointly file for patents, if the cooperation deals new intellectual property. The partnership is intended to complement and benefit both partners in their scientific and business progress.



MOLOGEN is focused on using its proprietary DNA technologies in the creation and development of treatment for high-unmet-need illnesses. Included are MOLOGEN's unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.
For its cell-based cancer therapies, MOLOGEN applies gene-modified and immunomodulated tumor cells having their origin in tumors from patients.
Tumor cells were subsequently cultivated and established as cell lines. MIDGE DNA constructs and the also DNA-based molecules are then used to modify these cell lines in culture (ex-vivo). Thereby, therapeutic vaccines are produced for the treatment of metastatic states of various cancers.
MOLOGEN AG currently built strategic alliances with Chinese biotechnology and pharmaceutical companies, to bring its products to the market more quickly and efficiently.
Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

About MEBO International Group
Mebo International Group and Professor Rong Xiang Xu, are the world wide leaders in the treatment of severe burn wounds of the skin by their proprietary therapy named MEBT (Moist-Exposed Burns Therapy). For MEBT, they use pharmaceutically plant extract MEBO (Moist-Exposed Burns Ointment), which gave birth to the company's name. MEBT and MEBO generate a physiological ("natural") environment in and above the burnt layers of skin. This uniquely promotes the regeneration of skin from tissue stem cells. MEBT/MEBO is used and sold in 48 countries. Early in 2004, a textbook about MEBT/MEBO, entitled "Burns, Regenerative Medicine and Therapy", was published by the renowned Swiss Karger corporation (ISBN 3-8055-7661-7).
Now, through the selective addition of herbal extracts, Professor Xu succeeded in the induction of growth in a variety of other tissue stem cells in their natural environment (in situ). He even accomplished regeneration of tissues and functional organ units. In this context, he identified mixtures of herbal extracts, homing in on tumors, to promote the differentiation of tumor cells. Differentiation into regular tissue cells is one requirement for the prevention of metastases.

Contact MEBO:
Director of International Department
MEBO International Group
E-Mail: [email protected]
Telefon: +86 - 10 - 65279212
Fax: +86 - 10 - 65124361


Contact: Matthias Reichel
Phone: +49-30-84 17 88 - 0
Fax: +49-30-84 17 88 - 50
e-mail: [email protected]